Limits...
Long-Term Consequences of Hepatitis C Viral Clearance on the CD4 (+) T Cell Lymphocyte Course in HIV/HCV Coinfected Patients.

Dazley J, Sison R, Slim J - AIDS Res Treat (2015)

Bottom Line: Multiple linear regression analysis was performed to identify independent predictors of CD4 + T cell change following the anti-HCV treatment outcome.An insignificant mean increase of 77 cells/ll occurred in the non-SVR group within month 24 (P = 0.06).Variables associated with greater CD4 gains were higher nadir, lower preinterferon CD4 counts, and lower body mass index (BMI).

View Article: PubMed Central - PubMed

Affiliation: St. Michael's Medical Center, Seton Hall University, Newark, NJ 07102, USA.

ABSTRACT
The long-term impact of pegylated-interferon plus ribavirin treatment outcome on CD4 T cell course in patients coinfected with human immunodeficiency virus and hepatitis C virus is largely unclear in the literature. The aim of this study was to investigate the impact of HCV-RNA clearance by standard anti-HCV therapy on long-term CD4 cells recovery in HIV/HCV patients on successful combined antiretroviral therapy. We retrospectively enrolled HIV/HCV-coinfected patients on HIV medications and treated for hepatitis C. CD4 + T cell counts were registered at baseline and after hepatitis C therapy. Multiple linear regression analysis was performed to identify independent predictors of CD4 + T cell change following the anti-HCV treatment outcome. Of the 116 patients enrolled, 54 (46.6%) reached a sustained virological response. During a follow-up of 24 months, the SVR group showed a mean annual increase in CD4 + T cell from baseline of 84 cells/ll at 1 year and of a further 38 cells/ll within the second year (P = 0.01, 0.001, resp.). An insignificant mean increase of 77 cells/ll occurred in the non-SVR group within month 24 (P = 0.06). Variables associated with greater CD4 gains were higher nadir, lower preinterferon CD4 counts, and lower body mass index (BMI).

No MeSH data available.


Related in: MedlinePlus

Scatter plots demonstrating the average of CD4 T cell counts for subjects over time in years for nonspontaneous virological responders (a) and spontaneous virological responders (b).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4321096&req=5

fig1: Scatter plots demonstrating the average of CD4 T cell counts for subjects over time in years for nonspontaneous virological responders (a) and spontaneous virological responders (b).

Mentions: The slope (change in CD4 count per year) was significantly different between the two groups: SVR: increase of 83.8 in CD4 count per year (calculated to be the first 2.2 years) and non-SVR: increase of 44.9 in CD4 count per year (during first 2.2 years), P = 0.05. The long-term CD4 cell counts following the end of therapy showed an elevation in both groups, which was significant only in the SVR groups. There was no significant change in absolute CD4 count from baseline for the non-SVR group over 5 years, and the median value indicated that the levels of absolute CD4 counts were also similar. There were no differences in proportion of patients with significant fibrosis between the two groups. Table 1 shows the basic characteristics for each subject and Table 2 indicates the CD4 count difference before and after HCV therapy. Figure 1 demonstrates the natural slope seen at treatment start and continues for six years of SVR.


Long-Term Consequences of Hepatitis C Viral Clearance on the CD4 (+) T Cell Lymphocyte Course in HIV/HCV Coinfected Patients.

Dazley J, Sison R, Slim J - AIDS Res Treat (2015)

Scatter plots demonstrating the average of CD4 T cell counts for subjects over time in years for nonspontaneous virological responders (a) and spontaneous virological responders (b).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4321096&req=5

fig1: Scatter plots demonstrating the average of CD4 T cell counts for subjects over time in years for nonspontaneous virological responders (a) and spontaneous virological responders (b).
Mentions: The slope (change in CD4 count per year) was significantly different between the two groups: SVR: increase of 83.8 in CD4 count per year (calculated to be the first 2.2 years) and non-SVR: increase of 44.9 in CD4 count per year (during first 2.2 years), P = 0.05. The long-term CD4 cell counts following the end of therapy showed an elevation in both groups, which was significant only in the SVR groups. There was no significant change in absolute CD4 count from baseline for the non-SVR group over 5 years, and the median value indicated that the levels of absolute CD4 counts were also similar. There were no differences in proportion of patients with significant fibrosis between the two groups. Table 1 shows the basic characteristics for each subject and Table 2 indicates the CD4 count difference before and after HCV therapy. Figure 1 demonstrates the natural slope seen at treatment start and continues for six years of SVR.

Bottom Line: Multiple linear regression analysis was performed to identify independent predictors of CD4 + T cell change following the anti-HCV treatment outcome.An insignificant mean increase of 77 cells/ll occurred in the non-SVR group within month 24 (P = 0.06).Variables associated with greater CD4 gains were higher nadir, lower preinterferon CD4 counts, and lower body mass index (BMI).

View Article: PubMed Central - PubMed

Affiliation: St. Michael's Medical Center, Seton Hall University, Newark, NJ 07102, USA.

ABSTRACT
The long-term impact of pegylated-interferon plus ribavirin treatment outcome on CD4 T cell course in patients coinfected with human immunodeficiency virus and hepatitis C virus is largely unclear in the literature. The aim of this study was to investigate the impact of HCV-RNA clearance by standard anti-HCV therapy on long-term CD4 cells recovery in HIV/HCV patients on successful combined antiretroviral therapy. We retrospectively enrolled HIV/HCV-coinfected patients on HIV medications and treated for hepatitis C. CD4 + T cell counts were registered at baseline and after hepatitis C therapy. Multiple linear regression analysis was performed to identify independent predictors of CD4 + T cell change following the anti-HCV treatment outcome. Of the 116 patients enrolled, 54 (46.6%) reached a sustained virological response. During a follow-up of 24 months, the SVR group showed a mean annual increase in CD4 + T cell from baseline of 84 cells/ll at 1 year and of a further 38 cells/ll within the second year (P = 0.01, 0.001, resp.). An insignificant mean increase of 77 cells/ll occurred in the non-SVR group within month 24 (P = 0.06). Variables associated with greater CD4 gains were higher nadir, lower preinterferon CD4 counts, and lower body mass index (BMI).

No MeSH data available.


Related in: MedlinePlus